Since the engineering and first successful application of recombinant adeno-associated virus (rAAV) serotype 2 as a gene transfer vehicle in 1984 (ref. 1), numerous additional rAAV serotypes have been isolated and characterized. Although many of these viruses have shown robust transduction efficiencies in various organ systems throughout the body by means of simple systemic delivery methods, widespread transduction of the central nervous system (CNS) via relatively noninvasive methods has been elusive.
No takes yet. Share an insight, caveat, or question.
Manfredsson et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: